Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolite Identification and Material Balance of SP2086 in Healthy Volunteers
NCT02815748Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of retagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 up to 96 hours, Maximum Plasma Concentration of SP2086 Acid up to 96 hours and 2 more. Started Aug 2015; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02815748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815748.